2 completed, 1 withdrawn. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow VBP15 compound: new trials by email Literature Review of VBP15 compound trials Research Report on VBP15 compound
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) Pharmacokinetics Vamorolone, Midazolam - Drug Interaction | Phase 1 | Completed | Santhera Pharmaceuticals | 18 | 2024-08-13 | 2025-12-15 |
| Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects Vamorolone, Eplerenone, Fludrocortisone - Pharmacodynamic | Phase 1 | Completed | Santhera Pharmaceuticals | 30 | 2024-06-05 | 2025-09-11 |
| Proof of Concept Trial of Vamorolone in Pediatric Ulcerative Colitis Vamorolone 4% suspension for oral dosing - Pediatric Ulcerative Colitis | Phase 1 / Phase 2 | Withdrawn | ReveraGen BioPharma, Inc. | 2020-09-01 | 2020-09-29 |
Pediatric ulcerative colitis (1)
Santhera Pharmaceuticals (2) · ReveraGen BioPharma, Inc. (1)
Germany (2)
Laurie Conklin, MD (1) · Michael Lissy, MD (1) · Steffen Haffner, MD (1)